CMTS0929 for Inflammatory Bowel Disease
ConditionInflammatory Bowel Disease (IBD)
Trial statusNot yet recruiting
Trial phaseEarly Phase 1
Trial typeInterventional
Biological sexAll
Age18-75
SponsorThe Second Hospital of Nanjing Medical University
About this trial
This is a prospective, open-label, single-arm study to explore the safety and the efficacy of China Microbiota Transplantation System 0929 (CMTS0929) for patients with inflammatory bowel disease (IBD).
Eligibility criteria
Qualifiers
Patients diagnosed with inflammatory bowel disease (IBD) based on typical clinical symptoms, endoscopic findings, and histological criteria.
Aged between 18 and 75 years old, regardless of gender.
No history of using antibiotics, prebiotics, or probiotics within at least the past month.
Patients who can fully understand the content of the informed consent form for this trial and voluntarily sign the written informed consent.
Disqualifiers
Women who are pregnant or plan to become pregnant during the trial.
Patients who have any doubts about this technology or have a history of other risks.
Patients in the terminal stage of the disease or who may die during the study.
Patients with a history of antibiotic use within three months before transplantation or who have participated in other clinical trials.
Trial design
Treatments tested in this trial
- CMTS0929
Treatment groups
12 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov